1. Home
  2. MLYS vs MUX Comparison

MLYS vs MUX Comparison

Compare MLYS & MUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • MUX
  • Stock Information
  • Founded
  • MLYS 2019
  • MUX 1979
  • Country
  • MLYS United States
  • MUX Canada
  • Employees
  • MLYS N/A
  • MUX N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • MUX Precious Metals
  • Sector
  • MLYS Health Care
  • MUX Basic Materials
  • Exchange
  • MLYS Nasdaq
  • MUX Nasdaq
  • Market Cap
  • MLYS 590.3M
  • MUX 501.8M
  • IPO Year
  • MLYS 2023
  • MUX N/A
  • Fundamental
  • Price
  • MLYS $13.99
  • MUX $8.80
  • Analyst Decision
  • MLYS Strong Buy
  • MUX Strong Buy
  • Analyst Count
  • MLYS 2
  • MUX 2
  • Target Price
  • MLYS $30.00
  • MUX $15.63
  • AVG Volume (30 Days)
  • MLYS 152.5K
  • MUX 542.1K
  • Earning Date
  • MLYS 11-12-2024
  • MUX 11-05-2024
  • Dividend Yield
  • MLYS N/A
  • MUX N/A
  • EPS Growth
  • MLYS N/A
  • MUX N/A
  • EPS
  • MLYS N/A
  • MUX 2.07
  • Revenue
  • MLYS N/A
  • MUX $199,634,000.00
  • Revenue This Year
  • MLYS N/A
  • MUX $28.57
  • Revenue Next Year
  • MLYS N/A
  • MUX $11.77
  • P/E Ratio
  • MLYS N/A
  • MUX $4.48
  • Revenue Growth
  • MLYS N/A
  • MUX 47.02
  • 52 Week Low
  • MLYS $5.85
  • MUX $5.92
  • 52 Week High
  • MLYS $16.91
  • MUX $12.50
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 57.43
  • MUX 38.57
  • Support Level
  • MLYS $13.33
  • MUX $8.46
  • Resistance Level
  • MLYS $15.25
  • MUX $9.70
  • Average True Range (ATR)
  • MLYS 0.63
  • MUX 0.44
  • MACD
  • MLYS -0.01
  • MUX -0.18
  • Stochastic Oscillator
  • MLYS 59.25
  • MUX 21.90

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About MUX McEwen Mining Inc.

McEwen Mining Inc is a mining and minerals production and exploration company focused on precious and base minerals in Argentina, Mexico, and the United States. The company's overall revenue is principally derived from the production of gold and silver. The company owns and operates the wholly-owned El Gallo 1 mine in Mexico, and has a minority shareholding in the company that operates the San Jose mine in Argentina. More than half the company's gold output is produced by the El Gallo 1 mine. The remaining gold production, and the majority of silver production, is produced by the San Jose mine. Geographically, the majority is from Canada.

Share on Social Networks: